1
|
Luo J, Zhang M, Ye Q, Gao F, Xu W, Li B, Wang Q, Zhao L, Tan WS. A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice. Arch Virol 2024; 169:163. [PMID: 38990396 DOI: 10.1007/s00705-024-06082-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 05/13/2024] [Indexed: 07/12/2024]
Abstract
Antigenically divergent H7N9 viruses pose a potential threat to public health, with the poor immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines. In the present study, mice were immunized with various doses of a suspended-MDCK-cell-derived inactivated H7N9 vaccine, which was based on a low-pathogenic H7N9 virus, to assess cross-reactive immunity and cross-protection against antigenically divergent H7N9 viruses. We found that the CRX-527 adjuvant, a synthetic TLR4 agonist, significantly enhanced the humoral immune responses of the suspended-MDCK-cell-derived H7N9 vaccine, with significant antigen-sparing and immune-enhancing effects, including robust virus-specific IgG, hemagglutination-inhibiting (HI), neuraminidase-inhibiting (NI), and virus-neutralizing (VN) antibody responses, which are crucial for protection against influenza virus infection. Moreover, the CRX-527-adjuvanted H7N9 vaccine also elicited cross-protective immunity and cross-protection against a highly pathogenic H7N9 virus with a single vaccination. Notably, NI and VN antibodies might play an important role in cross-protection against lethal influenza virus infections. This study showed that a synthetic TLR4 agonist adjuvant has a potent immunopotentiating effect, which might be considered worth further development as a means of increasing vaccine effectiveness.
Collapse
Affiliation(s)
- Jian Luo
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China
- Shanghai Institute of Biological Products, Shanghai, China
| | - Min Zhang
- Shanghai Institute of Biological Products, Shanghai, China
| | - Qian Ye
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China
| | - Feixia Gao
- Shanghai Institute of Biological Products, Shanghai, China
| | - Wenting Xu
- Shanghai Institute of Biological Products, Shanghai, China
| | - Beibei Li
- Shanghai Institute of Biological Products, Shanghai, China
| | - Qi Wang
- Shanghai Institute of Biological Products, Shanghai, China
| | - Liang Zhao
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China
| | - Wen-Song Tan
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
| |
Collapse
|
2
|
Liu S, Li J, Cheng Q, Duan K, Wang Z, Yan S, Tian S, Wang H, Wu S, Lei X, Yang Y, Ma N. A Single-Step Method for Harvesting Influenza Viral Particles from MDCK Cell Culture Supernatant with High Yield and Effective Impurity Removal. Viruses 2024; 16:768. [PMID: 38793649 PMCID: PMC11125750 DOI: 10.3390/v16050768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Revised: 05/08/2024] [Accepted: 05/11/2024] [Indexed: 05/26/2024] Open
Abstract
Influenza vaccines, which are recommended by the World Health Organization (WHO), are the most effective preventive measure against influenza virus infection. Madin-Darby canine kidney (MDCK) cell culture is an emerging technology used to produce influenza vaccines. One challenge when purifying influenza vaccines using this cell culture system is to efficiently remove impurities, especially host cell double-stranded DNA (dsDNA) and host cell proteins (HCPs), for safety assurance. In this study, we optimized ion-exchange chromatography methods to harvest influenza viruses from an MDCK cell culture broth, the first step in influenza vaccine purification. Bind/elute was chosen as the mode of operation for simplicity. The anion-exchange Q chromatography method was able to efficiently remove dsDNA and HCPs, but the recovery rate for influenza viruses was low. However, the cation-exchange SP process was able to simultaneously achieve high dsDNA and HCP removal and high influenza virus recovery. For the SP process to work, the clarified cell culture broth needed to be diluted to reduce its ionic strength, and the optimal dilution rate was determined to be 1:2 with purified water. The SP process yielded a virus recovery rate exceeding 90%, as measured using a hemagglutination units (HAUs) assay, with removal efficiencies over 97% for HCPs and over 99% for dsDNA. Furthermore, the general applicability of the SP chromatography method was demonstrated with seven strains of influenza viruses recommended for seasonal influenza vaccine production, including H1N1, H3N2, B (Victoria), and B (Yamagata) strains, indicating that the SP process could be utilized as a platform process. The SP process developed in this study showed four advantages: (1) simple operation, (2) a high recovery rate for influenza viruses, (3) a high removal rate for major impurities, and (4) general applicability.
Collapse
Affiliation(s)
- Sixu Liu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
| | - Jingqi Li
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
- GenScript (Shanghai) Biotech Co., Ltd., Shanghai 200131, China
| | - Qingtian Cheng
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
| | - Kangyi Duan
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
| | - Zhan Wang
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China;
| | - Shuang Yan
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
| | - Shuaishuai Tian
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
| | - Hairui Wang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
- Qilu Pharmaceutical Co., Ltd., Jinan 250104, China
| | - Shaobin Wu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China
| | - Xinkui Lei
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China
| | - Yu Yang
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China;
| | - Ningning Ma
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
| |
Collapse
|
3
|
Li F, Liu B, Xiong Y, Zhang Z, Zhang Q, Qiu R, Peng F, Nian X, Wu D, Li X, Liu J, Li Z, Tu H, Wu W, Wang Y, Zhang J, Yang X. Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine. Vaccines (Basel) 2024; 12:138. [PMID: 38400122 PMCID: PMC10891636 DOI: 10.3390/vaccines12020138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 01/17/2024] [Accepted: 01/25/2024] [Indexed: 02/25/2024] Open
Abstract
H5N1 highly pathogenic avian influenza virus (HPAIV) infections pose a significant threat to human health, with a mortality rate of around 50%. Limited global approval of H5N1 HPAIV vaccines, excluding China, prompted the need to address safety concerns related to MDCK cell tumorigenicity. Our objective was to improve vaccine safety by minimizing residual DNA and host cell protein (HCP). We developed a downstream processing method for the cell-based H5N1 HPAIV vaccine, employing CaptoTM Core 700, a multimodal resin, for polishing. Hydrophobic-interaction chromatography (HIC) with polypropylene glycol as a functional group facilitated the reversible binding of virus particles for capture. Following the two-step chromatographic process, virus recovery reached 68.16%. Additionally, HCP and DNA levels were reduced to 2112.60 ng/mL and 6.4 ng/mL, respectively. Western blot, high-performance liquid chromatography (HPLC), and transmission electron microscopy (TEM) confirmed the presence of the required antigen with a spherical shape and appropriate particle size. Overall, our presented two-step downstream process demonstrates potential as an efficient and cost-effective platform technology for cell-based influenza (H5N1 HPAIV) vaccines.
Collapse
Affiliation(s)
- Fang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Bo Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Yu Xiong
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Zhegang Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Qingmei Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Ran Qiu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Feixia Peng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Dongping Wu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Xuedan Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Jing Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Ze Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Hao Tu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Wenyi Wu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Yu Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
- China National Biotec Group Company Limited, Beijing 100029, China
| |
Collapse
|
4
|
Nold NM, Pearson E, Heldt CL. Economic simulation of batch and continuous aqueous two-phase purification for viral products. Biotechnol Prog 2024; 40:e3397. [PMID: 37843875 DOI: 10.1002/btpr.3397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 09/07/2023] [Accepted: 09/22/2023] [Indexed: 10/17/2023]
Abstract
Vaccine manufacturing strategies that lower capital and production costs could improve vaccine access by reducing the cost per dose and encouraging localized manufacturing. Continuous processing is increasingly utilized to drive lower costs in biological manufacturing by requiring fewer capital and operating resources. Aqueous two-phase systems (ATPS) are a liquid-liquid extraction technique that enables continuous processing for viral vectors. To date, no economic comparison between viral vector purifications using traditional methods and ATPS has been published. In this work, economic simulations of traditional chromatography-based virus purification were compared to ATPS-based virus purification for the same product output in both batch and continuous modes. First, the modeling strategy was validated by re-creating a viral subunit manufacturing economic simulation. Then, ATPS capital and operating costs were compared to that of a traditional chromatography purification at multiple scales. At all scales, ATPS purification required less than 10% of the capital expenditure compared to chromatography-based purification. At an 11 kg per year production scale, the ATPS production costs were 50% less than purification with chromatography. Other chromatography configurations were explored, and may provide a production cost benefit to ATPS, but the purity and recovery were not experimentally verified. Batch and continuous ATPS were similar in capital and production costs. However, manual price adjustments suggest that continuous ATPS plant-building costs could be less than half that of batch ATPS at the 11 kg per year production scale. These simulations show the significant reduction in manufacturing costs that ATPS-based purification could deliver to the vaccine industry.
Collapse
Affiliation(s)
- Natalie M Nold
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| | - Eric Pearson
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
| | - Caryn L Heldt
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| |
Collapse
|
5
|
Lothert K, Harsy YMJ, Endres P, Müller E, Wolff MW. Evaluation of restricted access media for the purification of cell culture-derived Orf viruses. Eng Life Sci 2023; 23:e2300009. [PMID: 37664009 PMCID: PMC10472920 DOI: 10.1002/elsc.202300009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 07/06/2023] [Accepted: 07/10/2023] [Indexed: 09/05/2023] Open
Abstract
Recently, multimodal chromatography using restricted access media (RAM) for the purification of nanoparticles, such as viruses has regained increasing attention. These chromatography resins combine size exclusion on the particle shell and adsorptive interaction within the core. Accordingly, smaller process-related impurities, for example, DNA and proteins, can be retained, while larger product viruses can pass unhindered. We evaluated a range of currently available RAM, differing in the shells' pore cut-off and the core chemistry, for the purification of a cell culture-derived clarified model virus, namely the Orf virus (ORFV). We examined impurity depletion and product recovery as relevant criteria for the evaluation of column performance, as well as scale-up robustness and regeneration potential for evaluating a multiple use application. The results indicate that some columns, for example, the Capto Core, enable both a high DNA and protein removal, while others, for example, the Monomix Core 60 (MC60), are more suitable for DNA depletion. Furthermore, column regeneration is facilitated by using columns with larger shell pores (5000 vs. 700 kDa) and weaker binding interactions (anion exchange vs. multimodal). According to these findings, the choice of RAM resins should be selected according to the respective feed sample composition and the planned number of application cycles.
Collapse
Affiliation(s)
- Keven Lothert
- Institute of Bioprocess Engineering and Pharmaceutical TechnologyUniversity of Applied Sciences Mittelhessen (THM)GiessenGermany
| | - Yasmina M. J. Harsy
- Institute of Bioprocess Engineering and Pharmaceutical TechnologyUniversity of Applied Sciences Mittelhessen (THM)GiessenGermany
| | - Patrick Endres
- Tosoh Bioscience GmbH, Separations Business Unit ‐ EuropeGriesheimGermany
| | - Egbert Müller
- Tosoh Bioscience GmbH, Separations Business Unit ‐ EuropeGriesheimGermany
| | - Michael W. Wolff
- Institute of Bioprocess Engineering and Pharmaceutical TechnologyUniversity of Applied Sciences Mittelhessen (THM)GiessenGermany
| |
Collapse
|
6
|
Dwivedi M, Ghosh D, Saha A, Hasan S, Jindal D, Yadav H, Yadava A, Dwivedi M. Biochemistry of exosomes and their theranostic potential in human diseases. Life Sci 2023; 315:121369. [PMID: 36639052 DOI: 10.1016/j.lfs.2023.121369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 12/22/2022] [Accepted: 01/01/2023] [Indexed: 01/11/2023]
Abstract
Exosomes are classified as special extracellular vesicles in the eukaryotic system having diameters ranging from 30 to 120 nm. These vesicles carry various endogenous molecules including DNA, mRNA, microRNA, circular RNA, and proteins, crucial for numerous metabolic reactions and can be proposed as therapeutic or diagnostic targets for several disorders. The donor exosomes release their content to recipient cells and further establish the significant intercellular communication showing biological effects by triggering environmental alterations. Exosomes derived from mesenchymal and dendritic cells have demonstrated their therapeutic potential against organ injury. Yet, various intricacies are involved in exosomal transport and its inclusion in cancer and other disease pathogenesis needs to be explored. The exosomes represent profound potential as diagnostic biomarkers and therapeutic carriers in various pathophysiological conditions such as neurodegenerative diseases, chronic cancers, infectious diseases, female reproductive diseases and cardiovascular diseases. In the current study, we demonstrate the advancements in the implication of exosomes as one of the irrefutable prognostic biological targets in human health and diseases.
Collapse
Affiliation(s)
- Manish Dwivedi
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, India.
| | - Diya Ghosh
- Department of Biotechnology, Heritage Institute of Technology, Kolkata, West Bengal, India
| | - Anwesha Saha
- Department of Biotechnology, Heritage Institute of Technology, Kolkata, West Bengal, India
| | - Saba Hasan
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, India
| | - Divya Jindal
- Center for Emerging Diseases, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, India
| | - Hitendra Yadav
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, India
| | - Anuradha Yadava
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, India
| | - Medha Dwivedi
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, India
| |
Collapse
|
7
|
Neog S, Kumar S, Trivedi V. Isolation and characterization of Newcastle disease virus from biological fluids using column chromatography. Biomed Chromatogr 2023; 37:e5527. [PMID: 36250786 DOI: 10.1002/bmc.5527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 10/13/2022] [Accepted: 10/13/2022] [Indexed: 12/15/2022]
Abstract
Newcastle disease virus (NDV), belonging to the species avian orthoavulavirus 1, genus Orthoavulavirus, and family Paramyxoviridae, is responsible for Newcastle disease in poultry and other avian species. It has shown significant potential as an oncolytic virus and as a vector for vaccine delivery. NDV from infected biological serum is usually isolated or purified using density gradient ultracentrifugation. However, it has many disadvantages, including the fact that it is time consuming and can process only a limited quantity of sample at one time. In our study, native agarose gel electrophoresis and dynamic light scattering (DLS) analysis showed that NDV carried a net negative surface charge. Thus, we purified the virus using a HiTrap Q Sepharose Fast Flow anion exchange column with salt elution. Hemagglutination assay and plaque assay showed that the procedure yielded high-purity NDV particles with a recovery of more than 80%, and the process was fast and simple. The purity of the virus was confirmed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. The hydrodynamic volume and 'dry state' diameter of the purified NDV were analyzed using dynamic light scattering and transmission electron microscopy and were to be in the range of 200-300 nm. The viruses did not exhibit any deviation from their known physical properties. The genome of the virus was also detected by amplifying a 423-bp region using reverse transcription-polymerase chain reaction. Our study confirmed that NDV could be effectively purified using an anion exchange column. In addition, the procedure could be easily upscaled or downscaled based on the experimental requirements.
Collapse
Affiliation(s)
- Siddharth Neog
- Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology-Guwahati, Guwahati, India
| | - Sachin Kumar
- Viral Immunology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology-Guwahati, Guwahati, India
| | - Vishal Trivedi
- Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology-Guwahati, Guwahati, India
| |
Collapse
|
8
|
Song Y, Yang Y, Lin X, Zhao Q, Su Z, Ma G, Zhang S. Size exclusion chromatography using large pore size media induces adverse conformational changes of inactivated foot-and-mouth disease virus particles. J Chromatogr A 2022; 1677:463301. [DOI: 10.1016/j.chroma.2022.463301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 06/30/2022] [Accepted: 07/01/2022] [Indexed: 10/17/2022]
|
9
|
Fei C, Gao J, Fei C, Ma L, Zhu W, He L, Wu Y, Song S, Li W, Zhou J, Liao G. A flow-through chromatography purification process for Vero cell-derived influenza virus (H7N9). J Virol Methods 2021; 301:114408. [PMID: 34896455 DOI: 10.1016/j.jviromet.2021.114408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 10/29/2021] [Accepted: 12/07/2021] [Indexed: 11/29/2022]
Abstract
Immunization is the most effective way to respond to an influenza epidemic. To produce Vero cell-derived influenza vaccines, a more efficient, stable and economical purification process is required. In this study, we purified the H7N9 influenza virus grown in Vero cells that were cultured in a serum-free medium by using a combination of anion exchange chromatography (AEC) and ligand-activated core chromatography (LCC), which avoids the virus capture step. After purification, 99.95 % host cell DNA (hcDNA) (final concentration: 28.69 pg/dose) and 98.87 % host cell protein (HCP) (final concentration: 28.28 ng/dose) were removed. The albumin content was 11.36 ng/dose. All these remnants met the current Chinese Pharmacopoeia and WHO requirements. The final virus recovery rate was 58.74 %, with the concentration of hemagglutinin recorded at 132.12 μg/mL. The flow-through chromatography purification process represents an alternative to the existing processes for cell-derived influenza viruses and might be suitable for the purification of other viruses as well.
Collapse
Affiliation(s)
- ChengRui Fei
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - JingXia Gao
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - ChengHua Fei
- Kunming Maternal and Child Health Hospital, 650031, China
| | - Lei Ma
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - WenYong Zhu
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - LingYu He
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - YaNan Wu
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - ShaoHui Song
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - WeiDong Li
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China
| | - Jian Zhou
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China.
| | - GuoYang Liao
- Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, 650118, China.
| |
Collapse
|
10
|
Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography. BIOTECH 2021; 10:biotech10040022. [PMID: 35822796 PMCID: PMC9245476 DOI: 10.3390/biotech10040022] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 10/07/2021] [Accepted: 10/08/2021] [Indexed: 01/10/2023] Open
Abstract
This study reports a highly efficient, rapid one-step purification process for the production of the recombinant vesicular stomatitis virus-based vaccine, rVSV-∆G-spike (rVSV-S), recently developed by the Israel Institute for Biological Research (IIBR) for the prevention of COVID-19. Several purification strategies are evaluated using a variety of chromatography methods, including membrane adsorbers and packed-bed ion-exchange chromatography. Cell harvest is initially treated with endonuclease, clarified, and further concentrated by ultrafiltration before chromatography purification. The use of anion-exchange chromatography in all forms results in strong binding of the virus to the media, necessitating a high salt concentration for elution. The large virus and spike protein binds very strongly to the high surface area of the membrane adsorbents, resulting in poor virus recovery (<15%), while the use of packed-bed chromatography, where the surface area is smaller, achieves better recovery (up to 33%). Finally, a highly efficient chromatography purification process with CaptoTM Core 700 resin, which does not require binding and the elution of the virus, is described. rVSV-S cannot enter the inner pores of the resin and is collected in the flow-through eluent. Purification of the rVSV-S virus with CaptoTM Core 700 resulted in viral infectivity above 85% for this step, with the efficient removal of host cell proteins, consistent with regulatory requirements. Similar results were obtained without an initial ultrafiltration step.
Collapse
|
11
|
Norrrahim MNF, Mohd Kasim NA, Knight VF, Ong KK, Mohd Noor SA, Abdul Halim N, Ahmad Shah NA, Jamal SH, Janudin N, Misenan MSM, Ahmad MZ, Yaacob MH, Wan Yunus WMZ. Emerging Developments Regarding Nanocellulose-Based Membrane Filtration Material against Microbes. Polymers (Basel) 2021; 13:3249. [PMID: 34641067 PMCID: PMC8512566 DOI: 10.3390/polym13193249] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 09/21/2021] [Accepted: 09/22/2021] [Indexed: 02/06/2023] Open
Abstract
The wide availability and diversity of dangerous microbes poses a considerable problem for health professionals and in the development of new healthcare products. Numerous studies have been conducted to develop membrane filters that have antibacterial properties to solve this problem. Without proper protective filter equipment, healthcare providers, essential workers, and the general public are exposed to the risk of infection. A combination of nanotechnology and biosorption is expected to offer a new and greener approach to improve the usefulness of polysaccharides as an advanced membrane filtration material. Nanocellulose is among the emerging materials of this century and several studies have proven its use in filtering microbes. Its high specific surface area enables the adsorption of various microbial species, and its innate porosity can separate various molecules and retain microbial objects. Besides this, the presence of an abundant OH groups in nanocellulose grants its unique surface modification, which can increase its filtration efficiency through the formation of affinity interactions toward microbes. In this review, an update of the most relevant uses of nanocellulose as a new class of membrane filters against microbes is outlined. Key advancements in surface modifications of nanocellulose to enhance its rejection mechanism are also critically discussed. To the best of our knowledge, this is the first review focusing on the development of nanocellulose as a membrane filter against microbes.
Collapse
Affiliation(s)
- Mohd Nor Faiz Norrrahim
- Research Centre for Chemical Defence, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (M.N.F.N.); (K.K.O.); (S.A.M.N.); (N.J.)
| | - Noor Azilah Mohd Kasim
- Research Centre for Chemical Defence, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (M.N.F.N.); (K.K.O.); (S.A.M.N.); (N.J.)
- Department of Chemistry and Biology, Centre for Defence Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (N.A.A.S.); (S.H.J.)
| | - Victor Feizal Knight
- Research Centre for Chemical Defence, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (M.N.F.N.); (K.K.O.); (S.A.M.N.); (N.J.)
| | - Keat Khim Ong
- Research Centre for Chemical Defence, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (M.N.F.N.); (K.K.O.); (S.A.M.N.); (N.J.)
- Department of Chemistry and Biology, Centre for Defence Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (N.A.A.S.); (S.H.J.)
| | - Siti Aminah Mohd Noor
- Research Centre for Chemical Defence, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (M.N.F.N.); (K.K.O.); (S.A.M.N.); (N.J.)
- Department of Chemistry and Biology, Centre for Defence Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (N.A.A.S.); (S.H.J.)
| | - Norhana Abdul Halim
- Department of Physics, Centre for Defence Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia;
| | - Noor Aisyah Ahmad Shah
- Department of Chemistry and Biology, Centre for Defence Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (N.A.A.S.); (S.H.J.)
| | - Siti Hasnawati Jamal
- Department of Chemistry and Biology, Centre for Defence Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (N.A.A.S.); (S.H.J.)
| | - Nurjahirah Janudin
- Research Centre for Chemical Defence, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; (M.N.F.N.); (K.K.O.); (S.A.M.N.); (N.J.)
| | - Muhammad Syukri Mohamad Misenan
- Department of Chemistry, College of Arts and Science, Yildiz Technical University, Davutpasa Campus, Esenler, Istanbul 34220, Turkey;
| | - Muhammad Zamharir Ahmad
- Biotechnology and Nanotechnology Research Centre, Malaysia Agricultural Research and Development Institute, Persiaran MARDI-UPM, Serdang 43400, Selangor, Malaysia;
| | - Mohd Hanif Yaacob
- Wireless and Photonics Network Research Centre (WiPNET), Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia;
| | - Wan Md Zin Wan Yunus
- Research Centre for Tropicalisation, Universiti Pertahanan Nasional Malaysia, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia
| |
Collapse
|
12
|
Gränicher G, Babakhani M, Göbel S, Jordan I, Marichal-Gallardo P, Genzel Y, Reichl U. A high cell density perfusion process for Modified Vaccinia virus Ankara production: Process integration with inline DNA digestion and cost analysis. Biotechnol Bioeng 2021; 118:4720-4734. [PMID: 34506646 DOI: 10.1002/bit.27937] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 07/10/2021] [Accepted: 09/01/2021] [Indexed: 12/21/2022]
Abstract
By integrating continuous cell cultures with continuous purification methods, process yields and product quality attributes have been improved over the last 10 years for recombinant protein production. However, for the production of viral vectors such as Modified Vaccinia virus Ankara (MVA), no such studies have been reported although there is an increasing need to meet the requirements for a rising number of clinical trials against infectious or neoplastic diseases. Here, we present for the first time a scalable suspension cell (AGE1.CR.pIX cells) culture-based perfusion process in bioreactors integrating continuous virus harvesting through an acoustic settler with semi-continuous chromatographic purification. This allowed obtaining purified MVA particles with a space-time yield more than 600% higher for the integrated perfusion process (1.05 × 1011 TCID50 /Lbioreactor /day) compared to the integrated batch process. Without further optimization, purification by membrane-based steric exclusion chromatography resulted in an overall product recovery of 50.5%. To decrease the level of host cell DNA before chromatography, a novel inline continuous DNA digestion step was integrated into the process train. A detailed cost analysis comparing integrated production in batch versus production in perfusion mode showed that the cost per dose for MVA was reduced by nearly one-third using this intensified small-scale process.
Collapse
Affiliation(s)
- Gwendal Gränicher
- Bioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
| | - Masoud Babakhani
- Bioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.,Chair for Bioprocess Engineering, Faculty of Process- and Systems Engineering, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
| | - Sven Göbel
- Bioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.,Institute of Biochemical Engineering, Faculty 4 - Energy-, Process- and Bio-Engineering, University of Stuttgart, Stuttgart, Germany
| | | | - Pavel Marichal-Gallardo
- Bioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
| | - Yvonne Genzel
- Bioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
| | - Udo Reichl
- Bioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.,Chair for Bioprocess Engineering, Faculty of Process- and Systems Engineering, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
| |
Collapse
|
13
|
B Carvalho S, Peixoto C, T Carrondo MJ, S Silva RJ. Downstream processing for influenza vaccines and candidates: An update. Biotechnol Bioeng 2021; 118:2845-2869. [PMID: 33913510 DOI: 10.1002/bit.27803] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 04/10/2021] [Accepted: 04/16/2021] [Indexed: 02/07/2023]
Abstract
Seasonal and pandemic influenza outbreaks present severe health and economic burdens. To overcome limitations on influenza vaccines' availability and effectiveness, researchers chase universal vaccines providing broad, long-lasting protection against multiple influenza subtypes, and including pandemic ones. Novel influenza vaccine designs are under development, in clinical trials, or reaching the market, namely inactivated, or live-attenuated virus, virus-like particles, or recombinant antigens, searching for improved effectiveness; all these bring downstream processing (DSP) new challenges. Having to deal with new influenza strains, including pandemics, requires shorter development time, driving the development of faster bioprocesses. To cope with better upstream processes, new regulatory demands for quality and safety, and cost reduction requirements, new unit operations and integrated processes are increasing DSP efficiency for novel vaccine formats. This review covers recent advances in DSP strategies of different influenza vaccine formats. Focus is given to the improvements on relevant state-of-the-art unit operations, from harvest and clarification to purification steps, ending with sterile filtration and formulation. The development of more efficient unit operations to cope with biophysical properties of the new candidates is discussed: emphasis is given to the design of new stationary phases, 3D printing approaches, and continuous processing tools, such as continuous chromatography. The impact of the production platforms and vaccine designs on the downstream operations for the different influenza vaccine formats approved for this season are highlighted.
Collapse
Affiliation(s)
- Sofia B Carvalho
- Animal Cell Technology Unit, iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.,Animal Cell Technology Unit, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal
| | - Cristina Peixoto
- Animal Cell Technology Unit, iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.,Animal Cell Technology Unit, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal
| | - Manuel J T Carrondo
- Animal Cell Technology Unit, iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal
| | - Ricardo J S Silva
- Animal Cell Technology Unit, iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.,Animal Cell Technology Unit, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal
| |
Collapse
|
14
|
A new and simplified anion exchange chromatographic process for the purification of cell-grown influenza A H1N1 virus. Sep Purif Technol 2021. [DOI: 10.1016/j.seppur.2021.118412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
15
|
Lin Y, Anderson JD, Rahnama LMA, Gu SV, Knowlton AA. Exosomes in disease and regeneration: biological functions, diagnostics, and beneficial effects. Am J Physiol Heart Circ Physiol 2020; 319:H1162-H1180. [PMID: 32986962 PMCID: PMC7792703 DOI: 10.1152/ajpheart.00075.2020] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 07/30/2020] [Accepted: 08/20/2020] [Indexed: 12/12/2022]
Abstract
Exosomes are a subtype of extracellular vesicles. They range from 30 to 150 nm in diameter and originate from intraluminal vesicles. Exosomes were first identified as the mechanism for releasing unnecessary molecules from reticulocytes as they matured to red blood cells. Since then, exosomes have been shown to be secreted by a broad spectrum of cells and play an important role in the cardiovascular system. Different stimuli are associated with increased exosome release and result in different exosome content. The release of harmful DNA and other molecules via exosomes has been proposed as a mechanism to maintain cellular homeostasis. Because exosomes contain parent cell-specific proteins on the membrane and in the cargo that is delivered to recipient cells, exosomes are potential diagnostic biomarkers of various types of diseases, including cardiovascular disease. As exosomes are readily taken up by other cells, stem cell-derived exosomes have been recognized as a potential cell-free regenerative therapy to repair not only the injured heart but other tissues as well. The objective of this review is to provide an overview of the biological functions of exosomes in heart disease and tissue regeneration. Therefore, state-of-the-art methods for exosome isolation and characterization, as well as approaches to assess exosome functional properties, are reviewed. Investigation of exosomes provides a new approach to the study of disease and biological processes. Exosomes provide a potential "liquid biopsy," as they are present in most, if not all, biological fluids that are released by a wide range of cell types.
Collapse
Affiliation(s)
- Yun Lin
- Molecular and Cellular Cardiology, Cardiovascular Medicine, University of California, Davis, California
| | | | - Lily M A Rahnama
- Molecular and Cellular Cardiology, Cardiovascular Medicine, University of California, Davis, California
| | - Shenwen V Gu
- Molecular and Cellular Cardiology, Cardiovascular Medicine, University of California, Davis, California
| | - Anne A Knowlton
- Molecular and Cellular Cardiology, Cardiovascular Medicine, University of California, Davis, California
| |
Collapse
|
16
|
Lothert K, Dekevic G, Loewe D, Salzig D, Czermak P, Wolff MW. Upstream and Downstream Processes for Viral Nanoplexes as Vaccines. Methods Mol Biol 2020; 2183:217-248. [PMID: 32959247 DOI: 10.1007/978-1-0716-0795-4_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
The increasing medical interest in viral nanoplexes, such as viruses or virus-like particles used for vaccines, gene therapy products, or oncolytic agents, raises the need for fast and efficient production processes. In general, these processes comprise upstream and downstream processing. For the upstream process, efficiency is mainly characterized by robustly achieving high titer yields, while reducing process times and costs with regard to the cell culture medium, the host cell selection, and the applied process conditions. The downstream part, on the other hand, should effectively remove process-related contaminants, such as host cells/cell debris as well as host cell DNA and proteins, while maintaining product stability and reducing product losses. This chapter outlines a combination of process steps to successfully produce virus particles in the controlled environment of a stirred tank bioreactor, combined with a platform-based purification approach using filtration-based clarification and steric exclusion chromatography. Additionally, suggestions for off-line analytics in terms of virus characterization and quantification as well as for contaminant estimation are provided.
Collapse
Affiliation(s)
- Keven Lothert
- Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen, Germany
| | - Gregor Dekevic
- Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen, Germany
| | - Daniel Loewe
- Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen, Germany
| | - Denise Salzig
- Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen, Germany
| | - Peter Czermak
- Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen, Germany.,Faculty of Biology and Chemistry, Justus-Liebig-University Giessen, Giessen, Germany.,Division Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Giessen, Germany
| | - Michael W Wolff
- Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen, Germany.
| |
Collapse
|
17
|
Purification Methods and the Presence of RNA in Virus Particles and Extracellular Vesicles. Viruses 2020; 12:v12090917. [PMID: 32825599 PMCID: PMC7552034 DOI: 10.3390/v12090917] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 08/12/2020] [Accepted: 08/18/2020] [Indexed: 12/17/2022] Open
Abstract
The fields of extracellular vesicles (EV) and virus infections are marred in a debate on whether a particular mRNA or non-coding RNA (i.e., miRNA) is packaged into a virus particle or copurifying EV and similarly, whether a particular mRNA or non-coding RNA is contained in meaningful numbers within an EV. Key in settling this debate, is whether the purification methods are adequate to separate virus particles, EV and contaminant soluble RNA and RNA:protein complexes. Differential centrifugation/ultracentrifugation and precipitating agents like polyethylene glycol are widely utilized for both EV and virus purifications. EV are known to co-sediment with virions and other particulates, such as defective interfering particles and protein aggregates. Here, we discuss how encased RNAs from a heterogeneous mixture of particles can be distinguished by different purification methods. This is particularly important for subsequent interpretation of whether the RNA associated phenotype is contributed solely by virus or EV particles or a mixture of both. We also discuss the discrepancy of miRNA abundance in EV from different input material.
Collapse
|
18
|
Lothert K, Pagallies F, Feger T, Amann R, Wolff MW. Selection of chromatographic methods for the purification of cell culture-derived Orf virus for its application as a vaccine or viral vector. J Biotechnol 2020; 323:62-72. [PMID: 32763261 PMCID: PMC7403136 DOI: 10.1016/j.jbiotec.2020.07.023] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 07/23/2020] [Accepted: 07/31/2020] [Indexed: 12/02/2022]
Abstract
Estimation of the isoelectric point and size of Vero cell-derived Orf virus. Limited dynamic binding capacity of tested Orf virus to sulfated cellulose. Purification of Orf virus by steric exclusion chromatography lead to 84 % recovery. Hydrophobic interaction chromatography suitable for Orf virus purification. Promising unit operations for a scalable DSP to produce Orf virus viral vectors.
In recent years, the Orf virus has become a promising tool for protective recombinant vaccines and oncolytic therapy. However, suitable methods for an Orf virus production, including up- and downstream, are very limited. The presented study focuses on downstream processing, describing the evaluation of different chromatographic unit operations. In this context, ion exchange-, pseudo-affinity- and steric exclusion chromatography were employed for the purification of the cell culture-derived Orf virus, aiming at a maximum in virus recovery and contaminant depletion. The most promising chromatographic methods for capturing the virus particles were the steric exclusion- or salt-tolerant anion exchange membrane chromatography, recovering 84 % and 86 % of the infectious virus. Combining the steric exclusion chromatography with a subsequent Capto™ Core 700 resin or hydrophobic interaction membrane chromatography as a secondary chromatographic step, overall virus recoveries of up to 76 % were achieved. Furthermore, a complete cellular protein removal and a host cell DNA depletion of up to 82 % was possible for the steric exclusion membranes and the Capto™ Core 700 combination. The study reveals a range of possible unit operations suited for the chromatographic purification of the cell culture-derived Orf virus, depending on the intended application, i.e. a human or veterinary use, and the required purity.
Collapse
Affiliation(s)
- Keven Lothert
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen (THM), Giessen, Germany
| | - Felix Pagallies
- Department of Immunology, University of Tuebingen, Tuebingen, Germany
| | - Thomas Feger
- Department of Immunology, University of Tuebingen, Tuebingen, Germany
| | - Ralf Amann
- Department of Immunology, University of Tuebingen, Tuebingen, Germany
| | - Michael W Wolff
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen (THM), Giessen, Germany; Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Giessen, Germany.
| |
Collapse
|
19
|
Yang Y, Song Y, Lin X, Li S, Li Z, Zhao Q, Ma G, Zhang S, Su Z. Mechanism of bio-macromolecule denaturation on solid-liquid surface of ion-exchange chromatographic media - A case study for inactivated foot-and-mouth disease virus. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1142:122051. [PMID: 32145639 DOI: 10.1016/j.jchromb.2020.122051] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 02/25/2020] [Accepted: 02/27/2020] [Indexed: 01/26/2023]
Abstract
Destruction of assembly structures has been identified as a major cause for activity loss of virus and virus-like particles during their chromatographic process. A deep insight into the denaturation process at the solid-liquid interfaces is important for rational design of purification. In this study, in-situ differential scanning calorimetry (DSC) was employed to study the dissociation process of inactivated foot-and-mouth disease virus (FMDV) during ion exchange chromatography (IEC) at different levels of pH. The intact FMDV known as 146S and the dissociation products were quantified by high performance size exclusion chromatography (HPSEC) and the thermo-stability of 146S on-column was monitored in-situ by DSC. Serious dissociation was found at pH 7.0 and pH 8.0, leading to low 146S recoveries of 12.3% and 43.7%, respectively. The elution profiles from IEC and HPSEC combined with the thermal transition temperatures of 146S dissociation (Tm1) from DSC suggested two denaturation mechanisms that the 146S dissociation occurred on-column after adsorption at pH 7.0 and during elution step at pH 8.0. By appending different excipients including sucrose, the improvement of 146S recovery and reduced dissociation was found highly correlated to increment of 146S stability on-column detected by DSC. The highest recovery of 99.9% and the highest Tm1 of 54.49 °C were obtained at pH 9.0 with 20% (w/v) sucrose. According to chromatographic behaviors and Tm1, three different dissociation processes in IEC were discussed. The study provides a perspective to understand the denaturation process of assemblies during chromatography, and also supplies a strategy to improve assembly recovery.
Collapse
Affiliation(s)
- Yanli Yang
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Yanmin Song
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China
| | - Xuan Lin
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China
| | - Shuai Li
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China
| | - Zhengjun Li
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Qizu Zhao
- China Institute of Veterinary Drug Control, Beijing 100081, PR China
| | - Guanghui Ma
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Songping Zhang
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
| | - Zhiguo Su
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
| |
Collapse
|
20
|
Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance. J Pharm Anal 2020; 10:291-312. [PMID: 32292625 PMCID: PMC7104128 DOI: 10.1016/j.jpha.2020.01.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 01/10/2020] [Accepted: 01/11/2020] [Indexed: 12/20/2022] Open
Abstract
Viruses still pose a significant threat to human and animal health worldwide. In the fight against viral infections, high-purity viral stocks are needed for manufacture of safer vaccines. It is also a priority to ensure the viral safety of biopharmaceuticals such as blood products. Chromatography techniques are widely implemented at both academic and industrial levels in the purification of viral particles, whole viruses and virus-like particles to remove viral contaminants from biopharmaceutical products. This paper focuses on polysaccharide adsorbents, particulate resins and membrane adsorbers, used in virus purification/removal chromatography processes. Different chromatographic modes are surveyed, with particular attention to ion exchange and affinity/pseudo-affinity adsorbents among which commercially available agarose-based resins (Sepharose®) and cellulose-based membrane adsorbers (Sartobind®) occupy a dominant position. Mainly built on the development of new ligands coupled to conventional agarose/cellulose matrices, the development perspectives of polysaccharide-based chromatography media in this antiviral area are stressed in the conclusive part. Chromatography has been and is still extensively implemented in virus purification/removal downstream processes. Typical application fields are the manufacturing of purified viral vaccines and virus-free biopharmaceuticals. Agarose and cellulose remain the primary polysaccharide bases for chromatography adsorbents in such virus-related applications. Present R&D studies mainly focus on multimodal chromatography and affinity ligands.
Collapse
|
21
|
Loewe D, Dieken H, Grein TA, Weidner T, Salzig D, Czermak P. Opportunities to debottleneck the downstream processing of the oncolytic measles virus. Crit Rev Biotechnol 2020; 40:247-264. [PMID: 31918573 DOI: 10.1080/07388551.2019.1709794] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Oncolytic viruses (including measles virus) offer an alternative approach to reduce the high mortality rate of late-stage cancer. Several measles virus strains infect and lyse cancer cells efficiently, but the broad application of this therapeutic concept is hindered by the large number of infectious particles required (108-1012 TCID50 per dose). The manufacturing process must, therefore, achieve high titers of oncolytic measles virus (OMV) during upstream production and ensure that the virus product is not damaged during purification by applying appropriate downstream processing (DSP) unit operations. DSP is currently a production bottleneck because there are no specific platforms for OMV. Infectious OMV must be recovered as intact, enveloped particles, and host cell proteins and DNA must be reduced to acceptable levels to meet regulatory guidelines that were developed for virus-based vaccines and gene therapy vectors. Handling such high viral titers and process volumes is technologically challenging and expensive. This review considers the state of the art in OMV purification and looks at promising DSP technologies. We discuss here the purification of other enveloped viruses where such technologies could also be applied to OMV. The development of DSP technologies tailored for enveloped viruses is necessary to produce sufficient titers for virotherapy, which could offer hope to millions of patients suffering from incurable cancer.
Collapse
Affiliation(s)
- Daniel Loewe
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Giessen, Germany.,Faculty of Biology and Chemistry, University of Giessen, Giessen, Germany
| | - Hauke Dieken
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Giessen, Germany
| | - Tanja A Grein
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Giessen, Germany
| | - Tobias Weidner
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Giessen, Germany
| | - Denise Salzig
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Giessen, Germany
| | - Peter Czermak
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Giessen, Germany.,Faculty of Biology and Chemistry, University of Giessen, Giessen, Germany.,Project Group Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Giessen, Germany
| |
Collapse
|
22
|
Use of sulfated cellulose membrane adsorbers for chromatographic purification of cell cultured-derived influenza A and B viruses. Sep Purif Technol 2019. [DOI: 10.1016/j.seppur.2019.05.101] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
23
|
Joshi PU, Turpeinen DG, Weiss M, Escalante-Corbin G, Schroeder M, Heldt CL. Tie line framework to optimize non-enveloped virus recovery in aqueous two-phase systems. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1126-1127:121744. [DOI: 10.1016/j.jchromb.2019.121744] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 07/18/2019] [Accepted: 08/02/2019] [Indexed: 01/01/2023]
|
24
|
Hydrophobic-interaction chromatography for purification of influenza A and B virus. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1117:103-117. [DOI: 10.1016/j.jchromb.2019.03.037] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 03/28/2019] [Accepted: 03/29/2019] [Indexed: 11/17/2022]
|
25
|
Kondylis P, Schlicksup CJ, Zlotnick A, Jacobson SC. Analytical Techniques to Characterize the Structure, Properties, and Assembly of Virus Capsids. Anal Chem 2019; 91:622-636. [PMID: 30383361 PMCID: PMC6472978 DOI: 10.1021/acs.analchem.8b04824] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Panagiotis Kondylis
- Department of Chemistry, Indiana University, Bloomington, IN 47405-7102, USA
| | - Christopher J. Schlicksup
- Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN 47405-7102, USA
| | - Adam Zlotnick
- Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN 47405-7102, USA
| | - Stephen C. Jacobson
- Department of Chemistry, Indiana University, Bloomington, IN 47405-7102, USA
| |
Collapse
|
26
|
Ratanapariyanuch K, Shim YY, Wiens DJ, Reaney MJT. Grain Thin Stillage Protein Utilization: A Review. J AM OIL CHEM SOC 2018. [DOI: 10.1002/aocs.12056] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | - Youn Young Shim
- Department of Plant Sciences; University of Saskatchewan; Saskatoon SK S7N 5A8 Canada
- Prairie Tide Chemicals Inc.; Saskatoon SK S7J 0R1 Canada
- Guangdong Saskatchewan Oilseed Joint Laboratory, Department of Food Science and Engineering; Jinan University; Guangzhou Guangdong 510632 China
| | - Daniel J. Wiens
- Department of Plant Sciences; University of Saskatchewan; Saskatoon SK S7N 5A8 Canada
| | - Martin J. T. Reaney
- Department of Plant Sciences; University of Saskatchewan; Saskatoon SK S7N 5A8 Canada
- Prairie Tide Chemicals Inc.; Saskatoon SK S7J 0R1 Canada
- Guangdong Saskatchewan Oilseed Joint Laboratory, Department of Food Science and Engineering; Jinan University; Guangzhou Guangdong 510632 China
| |
Collapse
|
27
|
Purification of cell culture-derived influenza A virus via continuous anion exchange chromatography on monoliths. Vaccine 2018; 36:3153-3160. [DOI: 10.1016/j.vaccine.2017.06.086] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 06/18/2017] [Accepted: 06/29/2017] [Indexed: 02/04/2023]
|
28
|
Ng HW, Lee MFX, Chua GK, Gan BK, Tan WS, Ooi CW, Tang SY, Chan ES, Tey BT. Size-selective purification of hepatitis B virus-like particle in flow-through chromatography: Types of ion exchange adsorbent and grafted polymer architecture. J Sep Sci 2018; 41:2119-2129. [PMID: 29427396 DOI: 10.1002/jssc.201700823] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 01/08/2018] [Accepted: 01/26/2018] [Indexed: 11/09/2022]
Abstract
Hepatitis B virus-like particles expressed in Escherichia coli were purified using anion exchange adsorbents grafted with polymer poly(oligo(ethylene glycol) methacrylate) in flow-through chromatography mode. The virus-like particles were selectively excluded, while the relatively smaller sized host cell proteins were absorbed. The exclusion of virus-like particles was governed by the accessibility of binding sites (the size of adsorbents and the charge of grafted dextran chains) as well as the architecture (branch-chain length) of the grafted polymer. The branch-chain length of grafted polymer was altered by changing the type of monomers used. The larger adsorbent (90 μm) had an approximately twofold increase in the flow-through recovery, as compared to the smaller adsorbent (30 μm). Generally, polymer-grafted adsorbents improved the exclusion of the virus-like particles. Overall, the middle branch-chain length polymer grafted on larger adsorbent showed optimal performance at 92% flow-through recovery with a purification factor of 1.53. A comparative study between the adsorbent with dextran grafts and the polymer-grafted adsorbent showed that a better exclusion of virus-like particles was achieved with the absorbent grafted with inert polymer. The grafted polymer was also shown to reduce strong interaction between binding sites and virus-like particles, which preserved the particles' structure.
Collapse
Affiliation(s)
- Hon Wei Ng
- Chemical Engineering Discipline, School of Engineering, Monash University Malaysia, Selangor, Malaysia
| | - Micky Fu Xiang Lee
- Chemical Engineering Discipline, School of Engineering, Monash University Malaysia, Selangor, Malaysia
| | - Gek Kee Chua
- Faculty of Chemical and Natural Resources Engineering, Universiti Malaysia Pahang, Pahang, Malaysia
| | - Bee Koon Gan
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia.,Institute of Bioscience, Universiti Putra Malaysia, Selangor, Malaysia
| | - Wen Siang Tan
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia.,Institute of Bioscience, Universiti Putra Malaysia, Selangor, Malaysia
| | - Chien Wei Ooi
- Chemical Engineering Discipline, School of Engineering, Monash University Malaysia, Selangor, Malaysia
| | - Siah Ying Tang
- Chemical Engineering Discipline, School of Engineering, Monash University Malaysia, Selangor, Malaysia
| | - Eng Seng Chan
- Chemical Engineering Discipline, School of Engineering, Monash University Malaysia, Selangor, Malaysia.,Advanced Engineering Platform, Monash University Malaysia, Selangor, Malaysia
| | - Beng Ti Tey
- Chemical Engineering Discipline, School of Engineering, Monash University Malaysia, Selangor, Malaysia.,Advanced Engineering Platform, Monash University Malaysia, Selangor, Malaysia
| |
Collapse
|
29
|
Asanzhanova NN, Ryskeldinova SZ, Chervyakova OV, Khairullin BM, Kasenov MM, Tabynov KK. Comparison of Different Methods of Purification and Concentration in Production of Influenza Vaccine. Bull Exp Biol Med 2017; 164:229-232. [DOI: 10.1007/s10517-017-3964-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Indexed: 12/12/2022]
|
30
|
Bilawchuk LM, Griffiths CD, Jensen LD, Elawar F, Marchant DJ. The Susceptibilities of Respiratory Syncytial Virus to Nucleolin Receptor Blocking and Antibody Neutralization are Dependent upon the Method of Virus Purification. Viruses 2017; 9:E207. [PMID: 28771197 PMCID: PMC5580464 DOI: 10.3390/v9080207] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 07/25/2017] [Accepted: 07/27/2017] [Indexed: 12/12/2022] Open
Abstract
Respiratory Syncytial Virus (RSV) that is propagated in cell culture is purified from cellular contaminants that can confound experimental results. A number of different purification methods have been described, including methods that utilize fast protein liquid chromatography (FPLC) and gradient ultracentrifugation. Thus, the constituents and experimental responses of RSV stocks purified by ultracentrifugation in sucrose and by FPLC were analyzed and compared by infectivity assay, Coomassie stain, Western blot, mass spectrometry, immuno-transmission electron microscopy (TEM), and ImageStream flow cytometry. The FPLC-purified RSV had more albumin contamination, but there was less evidence of host-derived exosomes when compared to ultracentrifugation-purified RSV as detected by Western blot and mass spectrometry for the exosome markers superoxide dismutase [Cu-Zn] (SOD1) and the tetraspanin CD63. Although the purified virus stocks were equally susceptible to nucleolin-receptor blocking by the DNA aptamer AS1411, the FPLC-purified RSV was significantly less susceptible to anti-RSV polyclonal antibody neutralization; there was 69% inhibition (p = 0.02) of the sucrose ultracentrifugation-purified RSV, 38% inhibition (p = 0.03) of the unpurified RSV, but statistically ineffective neutralization in the FPLC-purified RSV (22% inhibition; p = 0.30). The amount of RSV neutralization of the purified RSV stocks was correlated with anti-RSV antibody occupancy on RSV particles observed by immuno-TEM. RSV purified by different methods alters the stock composition and morphological characteristics of virions that can lead to different experimental responses.
Collapse
Affiliation(s)
- Leanne M Bilawchuk
- Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
| | - Cameron D Griffiths
- Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
| | - Lionel D Jensen
- Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
| | - Farah Elawar
- Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
| | - David J Marchant
- Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
| |
Collapse
|
31
|
Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza. PLoS One 2017; 12:e0180314. [PMID: 28662134 PMCID: PMC5491208 DOI: 10.1371/journal.pone.0180314] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Accepted: 06/13/2017] [Indexed: 11/27/2022] Open
Abstract
Vaccination is the most effective course of action to prevent influenza. About 150 million doses of influenza vaccines were distributed for the 2015–2016 season in the USA alone according to the Centers for Disease Control and Prevention. Vaccine dosage is calculated based on the concentration of hemagglutinin (HA), the main surface glycoprotein expressed by influenza which varies from strain to strain. Therefore yearly-updated strain-specific antibodies and calibrating antigens are required. Preparing these quantification reagents can take up to three months and significantly slows down the release of new vaccine lots. Therefore, to circumvent the need for strain-specific sera, two anti-HA monoclonal antibodies (mAbs) against a highly conserved sequence have been produced by immunizing mice with a novel peptide-conjugate. Immunoblots demonstrate that 40 strains of influenza encompassing HA subtypes H1 to H13, as well as B strains from the Yamagata and Victoria lineage were detected when the two mAbs are combined to from a pan-HA mAb cocktail. Quantification using this pan-HA mAbs cocktail was achieved in a dot blot assay and results correlated with concentrations measured in a hemagglutination assay with a coefficient of correlation of 0.80. A competitive ELISA was also optimised with purified viral-like particles. Regardless of the quantification method used, pan-HA antibodies can be employed to accelerate process development when strain-specific antibodies are not available, and represent a valuable tool in case of pandemics. These antibodies were also expressed in CHO cells to facilitate large-scale production using bioreactor technologies which might be required to meet industrial needs for quantification reagents. Finally, a simulation model was created to predict the binding affinity of the two anti-HA antibodies to the amino acids composing the highly conserved epitope; different probabilities of interaction between a given amino acid and the antibodies might explain the affinity of each antibody against different influenza strains.
Collapse
|
32
|
Heldt CL, Zahid A, Vijayaragavan KS, Mi X. Experimental and computational surface hydrophobicity analysis of a non-enveloped virus and proteins. Colloids Surf B Biointerfaces 2017; 153:77-84. [DOI: 10.1016/j.colsurfb.2017.02.011] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 01/08/2017] [Accepted: 02/09/2017] [Indexed: 12/01/2022]
|
33
|
Steppert P, Burgstaller D, Klausberger M, Kramberger P, Tover A, Berger E, Nöbauer K, Razzazi‐Fazeli E, Jungbauer A. Separation of HIV‐1 gag virus‐like particles from vesicular particles impurities by hydroxyl‐functionalized monoliths. J Sep Sci 2017; 40:979-990. [DOI: 10.1002/jssc.201600765] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 11/23/2016] [Accepted: 11/23/2016] [Indexed: 11/05/2022]
Affiliation(s)
- Petra Steppert
- Department of Biotechnology University of Natural Resources and Life Sciences Vienna Austria
| | - Daniel Burgstaller
- Department of Biotechnology University of Natural Resources and Life Sciences Vienna Austria
| | - Miriam Klausberger
- Department of Biotechnology University of Natural Resources and Life Sciences Vienna Austria
| | | | | | - Eva Berger
- Austrian Centre of Industrial Biotechnology Vienna Austria
| | - Katharina Nöbauer
- VetCore Facility for Research University of Veterinary Medicine Vienna Vienna Austria
| | | | - Alois Jungbauer
- Department of Biotechnology University of Natural Resources and Life Sciences Vienna Austria
- Austrian Centre of Industrial Biotechnology Vienna Austria
| |
Collapse
|
34
|
Steppert P, Burgstaller D, Klausberger M, Tover A, Berger E, Jungbauer A. Quantification and characterization of virus-like particles by size-exclusion chromatography and nanoparticle tracking analysis. J Chromatogr A 2017; 1487:89-99. [PMID: 28110946 DOI: 10.1016/j.chroma.2016.12.085] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 12/12/2016] [Accepted: 12/31/2016] [Indexed: 12/18/2022]
Abstract
The rapid quantification of enveloped virus-like particles (VLPs) requires orthogonal methods to obtain reliable results. Three methods-nanoparticle tracking analysis (NTA), size-exclusion HPLC (SE-HPLC) with UV detection, and detection with multi-angle light scattering (MALS)-for quantification of enveloped VLPs have been compared, and the lower and upper limits of detection and quantification have been evaluated. NTA directly counts the enveloped VLPs, and a particle number is obtained with a lower limit of detection (LLOD) of 1.7×107part/mL and lower limit of quantification (LLOQ) of 3.4×108part/mL. SE-HPLC with UV detection was calibrated with standards characterized by NTA, and a LLOD of 6.9×109part/mL and LLOQ of 2.1×1010part/mL were found. SE-HPLC with MALS does not require a pre-calibrated sample because with a spherical model based on the Rayleigh-Gans-Debye approximation, the particle concentration can be directly deduced from the scattered light. A LLOD of 4.8×108part/mL and LLOQ of 2.1×109part/mL were measured and substantially lower compared to the UV method. The absolute particle concentration measured by SE-HPLC-MALS is one order of magnitude lower compared to measurement by NTA, which is explained by the wide size distribution of an enveloped VLP suspension. The model used for evaluation of light scattering data assumes monodisperse, homogeneous, and spherical particles.
Collapse
Affiliation(s)
- Petra Steppert
- Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria
| | - Daniel Burgstaller
- Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria
| | - Miriam Klausberger
- Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria
| | | | | | - Alois Jungbauer
- Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria; ACIB GmbH, Vienna, Austria.
| |
Collapse
|
35
|
Surawathanawises K, Kundrod K, Cheng X. Microfluidic devices with templated regular macroporous structures for HIV viral capture. Analyst 2017; 141:1669-77. [PMID: 26899457 DOI: 10.1039/c5an02282g] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
There is a need to develop inexpensive, portable and easy-to-use devices for viral sample processing for resource-limited settings. Here we offer a solution to efficient virus capture by incorporating macroporous materials with regular structures into microfluidic devices for affinity chromatography. Two-dimensional simulations were first conducted to investigate the effects of two structures, a nanopost array and a spherical pore network, on nanoparticle capture. Then, the two structures were created in polymers by templating anodic aluminum oxide films and 3D close-packed silica particles, respectively. When the microdevices containing functionalized porous materials were tested for human immunodeficiency virus (HIV) isolation, capture efficiencies of 80-99% were achieved under a continuous flow. Comparatively, functionalized flatbed microchannels captured around 10% of HIV particles. As the characteristic dimensions of the nanostructures are tunable, such devices can be adapted for the capture of different submicron bioparticles. The high capture efficiency and easy-to-operate nature suit the needs of resource-limited settings and may find applications in point-of-care diagnostics.
Collapse
Affiliation(s)
| | - Kathryn Kundrod
- Bioengineering Program, Lehigh University, Bethlehem, PA 18015, USA.
| | - Xuanhong Cheng
- Department of Materials Science and Engineering, Lehigh University, Bethlehem, PA 18015, USA and Bioengineering Program, Lehigh University, Bethlehem, PA 18015, USA.
| |
Collapse
|
36
|
Marichal-Gallardo P, Pieler MM, Wolff MW, Reichl U. Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol. J Chromatogr A 2016; 1483:110-119. [PMID: 28069171 DOI: 10.1016/j.chroma.2016.12.076] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Revised: 12/12/2016] [Accepted: 12/27/2016] [Indexed: 01/08/2023]
Abstract
Steric exclusion chromatography has been used for the purification of proteins and bacteriophages using monoliths. The operation is carried out by mixing a crude sample containing the target species with a predetermined concentration and molecular weight of polyethylene glycol (PEG) and loading it onto a non-reactive hydrophilic surface. Product capture occurs by the mutual steric exclusion of PEG between the product and the matrix. Selectivity is significantly influenced by target product size. Product elution is achieved by decreasing the PEG concentration. In this study, a 75cm2 cellulose membrane adsorber was used for the purification of a clarified and inactivated influenza A virus broth produced in a 5L bioreactor using suspension Madin Darby canine kidney cells. Product recovery was above 95% based on hemagglutination activity and single radial immunodiffusion assays. Maximum depletion of double stranded host cell DNA and total protein was 99.7% and 92.4%, respectively. Purified virus particles showed no aggregation with a monodisperse peak around 84nm. 250mL of the clarified inactivated virus broth was purified within 40min. The surface area productivity based on the recovery of the viral hemagglutinin antigen was 28-50mgm-2h-1 depending on the feed and loading conditions.
Collapse
Affiliation(s)
- Pavel Marichal-Gallardo
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany.
| | - Michael M Pieler
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany
| | - Michael W Wolff
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany; Institute of Bioprocess Engineering and Pharmaceutical Technology, Technische Hochschule Mittelhessen, Wiesenstrasse 14, 35390 Gießen, Germany
| | - Udo Reichl
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany; Chair of Bioprocess Engineering, Otto-von-Guericke University Magdeburg, Universitätsplatz 2, 39106 Magdeburg, Germany
| |
Collapse
|
37
|
Shen C, Liu Q, Zhou Y, Ku Z, Wang L, Lan K, Ye X, Huang Z. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine 2016; 34:5005-5012. [DOI: 10.1016/j.vaccine.2016.08.033] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Revised: 08/06/2016] [Accepted: 08/10/2016] [Indexed: 01/02/2023]
|
38
|
Vajda J, Weber D, Stefaniak S, Hundt B, Rathfelder T, Müller E. Mono- and polyprotic buffer systems in anion exchange chromatography of influenza virus particles. J Chromatogr A 2016; 1448:73-80. [DOI: 10.1016/j.chroma.2016.04.047] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 04/14/2016] [Accepted: 04/18/2016] [Indexed: 11/28/2022]
|
39
|
Weigel T, Solomaier T, Wehmeyer S, Peuker A, Wolff MW, Reichl U. A membrane-based purification process for cell culture-derived influenza A virus. J Biotechnol 2015; 220:12-20. [PMID: 26712479 DOI: 10.1016/j.jbiotec.2015.12.022] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Revised: 12/13/2015] [Accepted: 12/15/2015] [Indexed: 11/24/2022]
Abstract
A simple membrane-based purification process for cell culture-derived influenza virus was established that relies on only two chromatographic unit operations to achieve the contamination limits required according to regulatory authorities. After clarification and concentration, a pseudo-affinity membrane adsorber (sulfated cellulose, SCMA) was applied for virus capture. The subsequent polishing step consisted of a salt-tolerant anion exchange membrane adsorber (STMA) to bind residual DNA. For the presented process neither a buffer exchange step nor a nuclease step for further DNA digestion were required. As a starting point, a two-salt strategy (including a polyvalent ion) was employed to screen STMA conditions in a 96-well plate format. After optimization on chromatographic laboratory scale, the virus recovery was up to 97% with a residual DNA level below 0.82%. In addition, the STMA was characterized regarding its dynamic binding capacity and the impact of flow rate on yields and contamination levels. Overall, the total virus yield for influenza virus A/PR/8/34 (H1/N1) of this two-step membrane process was 75%, while the protein and the DNA contamination level could be reduced to 24% and at least 0.5%, respectively. With 19.8μg protein and 1.2ng DNA per monovalent dose, this purity level complies with the limits of the European Pharmacopeia for cell culture-derived vaccines for human use. Overall, the presented downstream process might serve as a generic and economic platform technology for production of cell culture-derived viruses and viral vectors.
Collapse
Affiliation(s)
- Thomas Weigel
- Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany.
| | - Thomas Solomaier
- Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany; Faculty of Pharmaceutical Biotechnology, Biberach University of Applied Sciences, 88400 Biberach, Germany
| | - Sebastian Wehmeyer
- Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany; Department of Biotechnology, Bielefeld University of Applied Sciences, 33615 Bielefeld, Germany
| | - Alessa Peuker
- Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany; Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, 01968 Senftenberg, Germany
| | - Michael W Wolff
- Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany; Chair of Bioprocess Engineering, Otto-von-Guericke University, 39106 Magdeburg, Germany
| | - Udo Reichl
- Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany; Chair of Bioprocess Engineering, Otto-von-Guericke University, 39106 Magdeburg, Germany
| |
Collapse
|
40
|
Improving the downstream processing of vaccine and gene therapy vectors with continuous chromatography. ACTA ACUST UNITED AC 2015. [DOI: 10.4155/pbp.15.29] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Nestola P, Silva RJ, Peixoto C, Alves PM, Carrondo MJ, Mota JP. Robust design of adenovirus purification by two-column, simulated moving-bed, size-exclusion chromatography. J Biotechnol 2015; 213:109-19. [DOI: 10.1016/j.jbiotec.2015.01.030] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Revised: 01/19/2015] [Accepted: 01/26/2015] [Indexed: 11/30/2022]
|
42
|
Chung CJ, Grimm AL, Wilson CL, Balasuriya UBR, Chung G, Timoney PJ, Bandaranayaka-Mudiyanselage CB, Lee SS, McGuire TC. Enhanced sensitivity of an antibody competitive blocking enzyme-linked immunosorbent assay using Equine arteritis virus purified by anion-exchange membrane chromatography. J Vet Diagn Invest 2015; 27:728-38. [PMID: 26462762 DOI: 10.1177/1040638715606487] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In an effort to improve a competitive blocking enzyme-linked immunosorbent assay (cELISA) for antibody detection to Equine arteritis virus (EAV), antigen purified by anion-exchange membrane chromatography capsule (AEC) was evaluated. Virus purification by the AEC method was rapid and easily scalable. A comparison was made between virus purified by the AEC method with that obtained by differential centrifugation based on the following: 1) the relative purity and quality of EAV glycoprotein 5 (GP5) containing the epitope defined by monoclonal antibody 17B7, and 2) the relative sensitivity of a commercial antibody cELISA with the only change being the 2 purified antigens. On evaluation by Western blot using GP5-specific monoclonal antibody 17B7, the AEC-purified EAV contained 86% GP5 monomer whereas the differentially centrifuged EAV contained <29% of the monomer. Improvement of analytical sensitivity without sacrifice of analytical specificity was clearly evident when cELISAs prepared with EAV antigen by each purification method were evaluated using 7 sensitivity and specificity check sets. Furthermore, the AEC-purified EAV-based cELISA had 30-40% higher agreement with the virus neutralization (VN) test than the cELISA prepared with differentially centrifuged EAV based on testing 40 borderline EAV-seropositive samples as defined by the VN test. In addition, the AEC-purified cELISA had highly significant (P = 0.001) robustness indicated by intra-laboratory repeatability and interlaboratory reproducibility when evaluated with the sensitivity check sets. Thus, use of AEC-purified EAV in the cELISA should lead to closer harmonization of the cELISA with the World Organization for Animal Health-prescribed VN test.
Collapse
Affiliation(s)
- Chungwon J Chung
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Amanda L Grimm
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Carey L Wilson
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Udeni B R Balasuriya
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Grace Chung
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Peter J Timoney
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Chandima-Bandara Bandaranayaka-Mudiyanselage
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Stephen S Lee
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| | - Travis C McGuire
- VMRD Inc., Pullman, WA (Chung, Grimm, Wilson, Chung, Bandaranayaka-Mudiyanselage, McGuire)Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY (Balasuriya, Timoney)University of Idaho, Moscow, ID (Lee)
| |
Collapse
|
43
|
Li J, Liu G, Liu X, Yang J, Chang J, Zhang W, Yu XF. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine. Viruses 2015; 7:3891-909. [PMID: 26193302 PMCID: PMC4517132 DOI: 10.3390/v7072803] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2015] [Revised: 06/20/2015] [Accepted: 07/01/2015] [Indexed: 11/16/2022] Open
Abstract
Coxsackievirus A16 (CA16) and enterovirus 71 (EV71), both of which can cause hand, foot and mouth disease (HFMD), are responsible for large epidemics in Asian and Pacific areas. Although inactivated EV71 vaccines have completed testing in phase III clinical trials in Mainland China, CA16 vaccines are still under development. A Vero cell-based inactivated CA16 vaccine was developed by our group. Screening identified a CA16 vaccine strain (CC024) isolated from HFMD patients, which had broad cross-protective abilities and satisfied all requirements for vaccine production. Identification of the biological characteristics showed that the CA16CC024 strain had the highest titer (107.5 CCID50/mL) in Vero cells, which would benefit the development of an EV71/CA16 divalent vaccine. A potential vaccine manufacturing process was established, including the selection of optimal time for virus harvesting, membrane for diafiltration and concentration, gel-filtration chromatography for the down-stream virus purification and virus inactivation method. Altogether, the analyses suggested that the CC-16, a limiting dilution clone of the CC024 strain, with good genetic stability, high titer and broad-spectrum immunogenicity, would be the best candidate strain for a CA16 inactivated vaccine. Therefore, our study provides valuable information for the development of a Vero cell-based CA16 or EV71-CA16 divalent inactivated vaccine.
Collapse
Affiliation(s)
- Jingliang Li
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
| | - Guanchen Liu
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
| | - Xin Liu
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
| | - Jiaxin Yang
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
| | - Junliang Chang
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
| | - Wenyan Zhang
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
| | - Xiao-Fang Yu
- First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China.
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.
| |
Collapse
|
44
|
A hydrophobic interaction chromatography strategy for purification of inactivated foot-and-mouth disease virus. Protein Expr Purif 2015; 113:23-9. [PMID: 25957800 DOI: 10.1016/j.pep.2015.04.011] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 04/28/2015] [Accepted: 04/29/2015] [Indexed: 11/22/2022]
Abstract
A purification scheme based on hydrophobic interaction chromatography was developed to separate inactivated foot-and-mouth disease virus (FMDV) from crude supernatant. About 92% recovery and 8.8-fold purification were achieved on Butyl Sepharose 4 FF. Further purification on Superdex 200 resulted in another 29-fold purification, with 92% recovery. The columns were coupled through an intermediate ultrafiltration unit to concentrate the virus. The entire process was completed in about 3.5h, with 75% final FMDV recovery, and 247-fold purification. The final product had purity above 98%, with over 99.5% of host cell DNA removed. High-performance size exclusion chromatography (HPSEC), Western blot, dynamic light scattering (DLS), and transmission electron microscopy (TEM) indicated that the purified virus contained the required antigen, and was structurally intact with a spherical shape and a particle size of 28 nm.
Collapse
|
45
|
A flow-through chromatography process for influenza A and B virus purification. J Virol Methods 2014; 207:45-53. [DOI: 10.1016/j.jviromet.2014.06.019] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Revised: 06/20/2014] [Accepted: 06/24/2014] [Indexed: 12/22/2022]
|
46
|
Contreras-Gómez A, Sánchez-Mirón A, García-Camacho F, Molina-Grima E, Chisti Y. Protein production using the baculovirus-insect cell expression system. Biotechnol Prog 2014; 30:1-18. [PMID: 24265112 DOI: 10.1002/btpr.1842] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 11/12/2013] [Accepted: 11/12/2013] [Indexed: 12/21/2022]
Abstract
The baculovirus-insect cell expression system is widely used in producing recombinant proteins. This review is focused on the use of this expression system in developing bioprocesses for producing proteins of interest. The issues addressed include: the baculovirus biology and genetic manipulation to improve protein expression and quality; the suppression of proteolysis associated with the viral enzymes; the engineering of the insect cell lines for improved capability in glycosylation and folding of the expressed proteins; the impact of baculovirus on the host cell and its implications for protein production; the effects of the growth medium on metabolism of the host cell; the bioreactors and the associated operational aspects; and downstream processing of the product. All these factors strongly affect the production of recombinant proteins. The current state of knowledge is reviewed.
Collapse
|
47
|
Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purification. Vaccine 2014; 32:3721-4. [DOI: 10.1016/j.vaccine.2014.04.033] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/27/2014] [Accepted: 04/14/2014] [Indexed: 11/21/2022]
|
48
|
Nestola P, Silva RJS, Peixoto C, Alves PM, Carrondo MJT, Mota JPB. Adenovirus purification by two-column, size-exclusion, simulated countercurrent chromatography. J Chromatogr A 2014; 1347:111-21. [PMID: 24813933 DOI: 10.1016/j.chroma.2014.04.079] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2014] [Revised: 04/18/2014] [Accepted: 04/22/2014] [Indexed: 10/25/2022]
Abstract
Adenovirus serotype 5 (Ad5) was successfully separated by size-exclusion chromatography (SEC) using a simple, yet efficient, two-column, quasi-continuous, simulated moving-bed process operated in an open-loop configuration. The operating cycle is divided into two identical half-cycles, each of them consisting of the following sequence of sub-steps: (i) elution of the upstream column and direction of the effluent of the downstream column to waste; (ii) elution of the upstream column and redirection of its effluent to waste while the downstream column is fed with the clarified bioreaction bulk and its effluent collected as purified product; (iii) operation of the system as in step (i) but collecting the effluent of the downstream column as product; (iv) elution of the upstream column and direction of its effluent to waste while the flow through the downstream column is temporarily halted. Clearance of impurities, namely DNA and host cell protein (HCP), were experimentally assessed. The pilot-scale run yielded a virus recovery of 86%, and a clearance of 90% and 89% for DNA and HCP, respectively, without any fine tunning of the predetermined operating parameters. These figures compare very favorably against single-column batch chromatography for the same volume of size-exclusion resin. However, and most importantly, the virus yield was increased from 57% for the batch system to 86% for the two-column SEC process because of internal recycling of the mixed fractions of contaminated Ad5, even though the two-column process was operated strictly in an open-loop configuration. And last, but not least, the productivity was increased by 6-fold with the two-column process. In conclusion, the main drawbacks of size-exclusion chromatography, namely low productivity and low product titer, were overcome to a considerable extent by an innovative two-column configuration that keeps the mixed fractions inside the system at all times.
Collapse
Affiliation(s)
- Piergiuseppe Nestola
- Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, 2780-157 Oeiras, Portugal
| | - Ricardo J S Silva
- Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal
| | - Cristina Peixoto
- Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal
| | - Paula M Alves
- Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, 2780-157 Oeiras, Portugal
| | - Manuel J T Carrondo
- Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, 2780-157 Oeiras, Portugal; Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal
| | - José P B Mota
- Requimte/CQFB, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal
| |
Collapse
|
49
|
Banjac M, Roethl E, Gelhart F, Kramberger P, Jarc BL, Jarc M, Štrancar A, Muster T, Peterka M. Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography. Vaccine 2014; 32:2487-92. [DOI: 10.1016/j.vaccine.2014.02.086] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Revised: 02/06/2014] [Accepted: 02/25/2014] [Indexed: 12/31/2022]
|
50
|
Kröber T, Wolff M, Hundt B, Seidel-Morgenstern A, Reichl U. Continuous purification of influenza virus using simulated moving bed chromatography. J Chromatogr A 2013; 1307:99-110. [DOI: 10.1016/j.chroma.2013.07.081] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2012] [Revised: 07/18/2013] [Accepted: 07/22/2013] [Indexed: 11/16/2022]
|